BioSpace

Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’

RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.

By BioSpace

1 min read
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights